- Insulet Reports First Quarter 2024 Revenue Increase of 23% Year-Over-Year
- Insulet’s 2023 Sustainability Report Highlights Commitment to Product Accessibility and Responsible Growth
- Insulet to Announce First Quarter 2024 Financial Results on May 9, 2024
- Insulet Appoints Ana Maria Chadwick as Chief Financial Officer
- Insulet’s Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump Therapy
- Insulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
- Insulet Reports Full Year 2023 Revenue Increase of 30% (30% Constant Currency¹) and Fourth Quarter 2023 Revenue Increase of 38% Year-Over-Year (37% Constant Currency)
- Insulet to Present at The Raymond James & Associates 45th Annual Institutional Investors Conference
More ▼
Key statistics
On Thursday, Insulet Corp (PODD:NSQ) closed at 177.53, 41.10% above the 52 week low of 125.82 set on Oct 12, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 177.00 |
---|---|
High | 179.04 |
Low | 175.78 |
Bid | 168.20 |
Offer | 172.40 |
Previous close | 175.57 |
Average volume | 834.24k |
---|---|
Shares outstanding | 70.02m |
Free float | 69.79m |
P/E (TTM) | 63.00 |
Market cap | 12.43bn USD |
EPS (TTM) | 2.82 USD |
Data delayed at least 15 minutes, as of May 09 2024 21:00 BST.
More ▼